Interesting Images68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?Kunikowska, Jolanta MD, PhD; Kujda, Szymon BSc; Królicki, Leszek MD, PhDAuthor Information From the Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland. Received for publication September 27, 2019; revision accepted December 15, 2019. Conflicts of interest and sources of funding: none declared. Compliance with ethical standards: All authors declare that they have no conflict of interest in relation to this article. This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. An informed consent was obtained from all individual participants included in the study. Correspondence to: Jolanta Kunikowska, MD, PhD, Nuclear Medicine Department, Medical University of Warsaw, ul. Banacha 1 a, 02-097 Warsaw, Poland. E-mail: email@example.com. Online date: February 12, 2020 Clinical Nuclear Medicine: April 2020 - Volume 45 - Issue 4 - p e213-e214 doi: 10.1097/RLU.0000000000002966 Buy Metrics Abstract We report a case of a 59-year-old man with prostate adenocarcinoma, Gleason score 9 after prostatectomy and adjuvant radiotherapy. The patient showed biochemical recurrence. On standard 68Ga-PSMA PET/CT examination, 60 minutes postinjection, the PET/CT images showed only trace accumulation in the ureters. To identify lesions close to the ureters, imaging of the pelvis was performed 2 hours postinjection. The delayed image showed clearly visible increased uptake in a right internal iliac lymph node that was normal-sized by CT. The patient underwent radiotherapy with planning based on the 68Ga-PSMA PET/CT image. Follow-up testing showed prostate-specific antigen level reduction to 0.04 ng/mL. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.